ADEF
CGON icon

ABS Direct Equity Fund’s CG Oncology CGON Stock Holding History

ABS Direct Equity Fund’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$176K Buy
+2,600
New +$147K 0.13% 86

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABS Direct Equity Fund's CGON Position: Q1 2026 in Review

ABS Direct Equity Fund opened a new position in CG Oncology (CGON) in Q1 2026: 2,600 shares worth $176K. The stake represents 0.13% of the portfolio and ranks #86 among its holdings.

233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • ABS Direct Equity Fund held 2,600 shares of CG Oncology worth $176K as of Q1 2026.
  • CG Oncology was a new ABS Direct Equity Fund position in Q1 2026.
  • CG Oncology made up 0.13% of ABS Direct Equity Fund's portfolio in Q1 2026, its #86 holding.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.